Tryngolza (autoinjector) is a drug owned by Ionis Pharmaceuticals Inc. It is protected by 5 US drug patents filed in 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be May 01, 2034. Details of Tryngolza (autoinjector)'s patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire. | |||
| US9127276 | Conjugated antisense compounds and their use |
May, 2034
(8 years from now) | Active |
| US9181549 | Conjugated antisense compounds and their use |
May, 2034
(8 years from now) | Active |
| US9163239 | Compositions and methods for modulating apolipoprotein C-III expression |
May, 2034
(8 years from now) | Active |
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US9593333 | Modulation of apolipoprotein C-III (ApoCIII) expression in lipoprotein lipase deficient (LPLD) populations |
Feb, 2034
(8 years from now) | Active |
| US9157082 | Modulation of apolipoprotein CIII (ApoCIII) expression |
Apr, 2032
(6 years from now) | Active |
FDA has granted several exclusivities to Tryngolza (autoinjector). Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Tryngolza (autoinjector), regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Tryngolza (autoinjector).
Exclusivity Information
Tryngolza (autoinjector) holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2031. Details of Tryngolza (autoinjector)'s exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-515) | Dec 19, 2031 |
US patents provide insights into the exclusivity only within the United States, but Tryngolza (autoinjector) is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Tryngolza (autoinjector)'s family patents as well as insights into ongoing legal events on those patents.
Tryngolza (autoinjector)'s Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Tryngolza (autoinjector)'s generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be May 01, 2034 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Tryngolza (autoinjector) Generics:
There are no approved generic versions for Tryngolza (autoinjector) as of now.
About Tryngolza (autoinjector)
Tryngolza (Autoinjector) is a drug owned by Ionis Pharmaceuticals Inc. Tryngolza (Autoinjector) uses Olezarsen Sodium as an active ingredient. Tryngolza (Autoinjector) was launched by Ionis Pharms Inc in 2024.
Approval Date:
Tryngolza (autoinjector) was approved by FDA for market use on 19 December, 2024.
Active Ingredient:
Tryngolza (autoinjector) uses Olezarsen Sodium as the active ingredient. Check out other Drugs and Companies using Olezarsen Sodium ingredient
Dosage:
Tryngolza (autoinjector) is available in solution form for subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 80MG BASE/0.8ML (EQ 80MG BASE/0.8ML) | SOLUTION | Prescription | SUBCUTANEOUS |